BR112016006151A2 - imidazopiridazinas úteis como inibidores da via de sinalização do par-2 - Google Patents

imidazopiridazinas úteis como inibidores da via de sinalização do par-2

Info

Publication number
BR112016006151A2
BR112016006151A2 BR112016006151A BR112016006151A BR112016006151A2 BR 112016006151 A2 BR112016006151 A2 BR 112016006151A2 BR 112016006151 A BR112016006151 A BR 112016006151A BR 112016006151 A BR112016006151 A BR 112016006151A BR 112016006151 A2 BR112016006151 A2 BR 112016006151A2
Authority
BR
Brazil
Prior art keywords
compounds
par
inhibitors
signaling pathway
useful
Prior art date
Application number
BR112016006151A
Other languages
English (en)
Portuguese (pt)
Inventor
Liu Bingcan
Elie SAYEGH Camil
Sturino Claudio
Yannopoulos Constantin
Vallee Frederic
Szychowski Janek
Lacoste Jean-Eric
Martel Julien
J Farmer Luc
St-Onge Miguel
Bubenik Monica
Fournier Pierre-Andre
Lessard Stephanie
K Ramtohul Yeeman
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of BR112016006151A2 publication Critical patent/BR112016006151A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112016006151A 2013-09-25 2014-09-25 imidazopiridazinas úteis como inibidores da via de sinalização do par-2 BR112016006151A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361882173P 2013-09-25 2013-09-25
US201361901617P 2013-11-08 2013-11-08
PCT/US2014/057390 WO2015048245A1 (en) 2013-09-25 2014-09-25 Imidazopyridazines useful as inhibitors of the par-2 signaling pathway

Publications (1)

Publication Number Publication Date
BR112016006151A2 true BR112016006151A2 (pt) 2017-08-01

Family

ID=52293160

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016006151A BR112016006151A2 (pt) 2013-09-25 2014-09-25 imidazopiridazinas úteis como inibidores da via de sinalização do par-2

Country Status (12)

Country Link
US (2) US10030024B2 (zh)
EP (1) EP3049418A1 (zh)
JP (1) JP2016531864A (zh)
KR (1) KR20160060120A (zh)
CN (1) CN105683192A (zh)
AU (2) AU2014326596B2 (zh)
BR (1) BR112016006151A2 (zh)
CA (1) CA2924690A1 (zh)
HK (2) HK1223096A1 (zh)
IL (1) IL244739A0 (zh)
TW (1) TW201602109A (zh)
WO (1) WO2015048245A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048245A1 (en) 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
ES2909709T3 (es) * 2016-05-12 2022-05-10 Heptares Therapeutics Ltd Inhibidores del receptor 2 activado por proteasa
CA3024719A1 (en) * 2016-05-20 2017-11-23 Takeda Pharmaceutical Company Limited Treatment of pain
EP3497102B1 (de) 2016-08-15 2022-12-07 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
BR112019001968A2 (pt) 2016-08-31 2019-05-07 Eisai R&D Management Co., Ltd. composto pirazolo[1,5-a]pirimidina
WO2018057588A1 (en) * 2016-09-21 2018-03-29 Vertex Pharmaceuticals Incorporated Furo[3,2-b]pyridine compounds useful as inhibitors of the par-2 signaling pathway
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
WO2018145080A1 (en) * 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
AU2018344370C1 (en) 2017-10-04 2023-04-27 Bayer Aktiengesellschaft Derivatives of heterocyclic compounds as pest control agents
JP2021508692A (ja) * 2017-12-20 2021-03-11 武田薬品工業株式会社 プロテアーゼ活性化受容体−２の阻害剤
AU2019224410A1 (en) * 2018-02-26 2020-07-09 Eisai R&D Management Co., Ltd. Salt of pyrazolo[1,5-a]pyrimidine compound and crystals thereof
JP2021515783A (ja) 2018-03-12 2021-06-24 バイエル・アクチエンゲゼルシヤフト 害虫防除剤としての縮合二環式ヘテロ環式誘導体
KR20210005081A (ko) 2018-04-20 2021-01-13 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로시클렌 유도체
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
WO2022117882A2 (en) 2020-12-03 2022-06-09 Domain Therapeutics Novel par-2 inhibitors
EP4308577A1 (en) 2021-03-17 2024-01-24 F. Hoffmann-La Roche AG New thiadiazolopyrimidone derivatives
WO2023233033A1 (en) 2022-06-03 2023-12-07 Domain Therapeutics Novel par-2 inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01009871A (es) * 1999-04-01 2002-04-24 Pfizer Prod Inc Aminopiridinas como inhibidores de la sorbitol deshidrogenasa.
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
EP2336169A1 (en) 2000-04-21 2011-06-22 New England Medical Center Hospital G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
ATE541847T1 (de) * 2001-11-01 2012-02-15 Icagen Inc Pyrazolopyrimidine als natriumkanalblocker
JP2003286171A (ja) * 2002-03-28 2003-10-07 Sumitomo Pharmaceut Co Ltd Ｐａｒ阻害剤
GB0213286D0 (en) 2002-06-10 2002-07-24 Univ Edinburgh Par-2-Activating peptide derivative and pharmaceutical composition using the same
JP2004170323A (ja) * 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
JPWO2005030773A1 (ja) * 2003-09-26 2006-12-07 大日本住友製薬株式会社 新規ピラゾロピリミジン誘導体
US8268789B2 (en) 2004-09-30 2012-09-18 Kowa Company, Ltd. PAR-2 antagonists
WO2006070780A1 (ja) 2004-12-28 2006-07-06 Kowa Company, Ltd. Ｐａｒ－２アゴニスト
US8133864B2 (en) 2005-03-29 2012-03-13 Kowa Company, Ltd. PAR-2 agonist
US20080318960A1 (en) 2005-05-26 2008-12-25 Ethan Burstein PAR2-modulating compounds and their use
US20070123508A1 (en) 2005-05-27 2007-05-31 Roger Olsson PAR2-modulating compounds and their use
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
US9044510B2 (en) 2007-11-01 2015-06-02 Washington University Compositions and methods for treating pruritus
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
CA2733041A1 (en) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Effectors of par-2 activation and their use in the modulation of inflammation
US8852569B2 (en) 2008-08-28 2014-10-07 The General Hospital Corporation Prevention and treatment of itch with cysteine protease inhibition
AU2010233089B2 (en) 2009-04-10 2016-05-26 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (MMP-1)
EP2427205A2 (en) 2009-05-04 2012-03-14 INSERM - Institut National de la Santé et de la Recherche Médicale Par2 agonists for use in the treatment or prevention of influenza virus type a infections
US20120107329A1 (en) 2009-06-10 2012-05-03 University Of Maryland, Baltimore EGFR and PAR2 Regulation of Intestinal Permeability
JO3246B1 (ar) 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
EP2335717A1 (en) 2009-11-16 2011-06-22 Institut National De La Recherche Agronomique PAR-1 antagonists for use in the treatment or prevention of influenza virus type a infections
US8927503B2 (en) 2010-07-28 2015-01-06 The University Of Queensland Modulations of protease activated receptors
PL2610255T3 (pl) 2010-08-25 2016-08-31 Neopharm Co Ltd Związki 1H-benzo[d]imidazol-5-ilowe i kompozycja do leczenia chorób zapalnych
FR2969657B1 (fr) 2010-12-22 2014-02-07 Fabre Pierre Dermo Cosmetique Nouvelle bacterie et extraits de ladite bacterie et leur utilisation en dermatologie
US9745347B2 (en) 2010-12-30 2017-08-29 Hadasit Medical Research Services And Development Ltd. PAR1 and PAR2 c-tail peptides and peptide mimetics
GB201101517D0 (en) 2011-01-28 2011-03-16 Proximagen Ltd Receptor antagonists
WO2012139137A2 (en) 2011-04-08 2012-10-11 Tufts Medical Center, Inc. Pepducin design and use
KR101412119B1 (ko) 2011-09-29 2014-06-27 주식회사 펩트론 생리적 안정성을 증가시킨 ｐａｒ―2 활성화 펩타이드 및 이를 함유하는 약제학적 조성물
WO2013064583A1 (en) 2011-11-04 2013-05-10 Lipotec, S.A. Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
US9868763B2 (en) 2011-11-07 2018-01-16 The University Of Queensland Modulators of protease activated receptors
CA2923595C (en) 2012-05-18 2020-07-14 Tufts Medical Center, Inc. Polypeptide and lipophilic moiety conjugate compositions, formulations, and uses related thereto
GB201213700D0 (en) 2012-08-01 2012-09-12 Proximagen Ltd Receptor antagnists II
US9808505B2 (en) 2013-03-08 2017-11-07 Board Of Regents, The University Of Texas System Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein C receptors (EPCR)
WO2014173859A2 (en) 2013-04-22 2014-10-30 Institut National De La Recherche Agronomique Par-4 antagonists for use in the treatment or prevention of influenza virus type a infections
WO2015048245A1 (en) 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
US9790506B2 (en) 2013-10-02 2017-10-17 The Regents Of The University Of California Diagnostic and screening methods for atopic dermatitis
WO2015117956A1 (en) 2014-02-04 2015-08-13 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against par1
JP5719050B2 (ja) 2014-02-28 2015-05-13 ザ プロクター アンド ギャンブルカンパニー 角化細胞のｐａｒ２活性化を阻害するための組成物及び方法
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination
WO2016005369A1 (en) 2014-07-08 2016-01-14 Celltrend Gmbh Par2 antibodies for diagnosis of graft intolerance of a liver transplant
WO2016138132A1 (en) 2015-02-25 2016-09-01 The Trustees Of Columbia University In The City Of New York Dipeptidyl peptidase-iv(dpp4) inhibitors, methods and compositions for suppressing adipose tissue inflammation

Also Published As

Publication number Publication date
US20160311825A1 (en) 2016-10-27
US10030024B2 (en) 2018-07-24
CN105683192A (zh) 2016-06-15
HK1225386A1 (zh) 2017-09-08
WO2015048245A1 (en) 2015-04-02
AU2014326596B2 (en) 2018-12-13
JP2016531864A (ja) 2016-10-13
CA2924690A1 (en) 2015-04-02
TW201602109A (zh) 2016-01-16
EP3049418A1 (en) 2016-08-03
AU2014326596A1 (en) 2016-04-07
KR20160060120A (ko) 2016-05-27
IL244739A0 (en) 2016-04-21
HK1223096A1 (zh) 2017-07-21
AU2019201532A1 (en) 2019-03-28
US20190119282A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
BR112016006151A2 (pt) imidazopiridazinas úteis como inibidores da via de sinalização do par-2
MX2015007101A (es) Compuestos utiles como inhibidores de cinasa relacionada con ataxia telangiectasia mutada y rad3 (atr).
NZ700580A (en) Compounds useful as inhibitors of atr kinase and combination therapies thereof
CL2017002650A1 (es) Compuestos novedosos
IN2014KN00943A (zh)
WO2014143242A8 (en) Compounds useful as inhibitors of atr kinase
MX2012013082A (es) Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr.
MX2012013081A (es) Compuestos utiles como inhibidores de cinasa atr.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
EA201501122A8 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
BR112015022566A2 (pt) composto e composição farmacêutica
MX353461B (es) PROCESOS PARA PREPARAR COMPUESTOS ÚTILES COMO INHIBIDORES DE CINASA ATAXIA TELANGIECTASIA MUTADA Y Rad3 RELACIONADOS (ATR).
BR112014026952A2 (pt) derivados de aminopirimidina pirazol como moduladores lrrk2
EA201592144A1 (ru) Производное фенола, способ его получения и его применение в медицине
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
BR112015010136A2 (pt) derivados de oxazolidin-2-ona-pirimidina
BR112013030391A2 (pt) derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina
SA520412289B1 (ar) مركبات مثبط الهدف الميكانيكي للراباميسين

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]